Kevin Young

This profile gathers the share dealings of Kevin Young across 2 companies, led by Gilead Sciences, Inc. and IRulya Therapeutics Inc. We count 177 filings; the first trade dates from 2 February 2006 and the latest from 13 May 2019.

On the open market, the record shows 1 purchase worth €454k and 100 sales worth €69.0M. The net balance comes to €68.6M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 33 share grants and 43 option exercises. So far in 2020, the count stands at 1 purchase and no sales.

On 12 March 2020 came the latest disclosure, an open-market purchase for €454k in IRulya Therapeutics Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.